# Commission Implementing Decision (EU) 2020/1729 of 17 November 2020 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria and repealing Implementing Decision 2013/652/EU (notified under document C(2020) 7894) (Only the English version is authentic) (Text with EEA relevance), Division 4.2: Analytical methods for detection and antimicrobial susceptibility testing

Extent: E+W+S+N.I.

Member States shall use the epidemiological cut-off values and the concentration ranges set out in Tables 2, 3 and 4 below to determine the antimicrobial susceptibility of Salmonella spp., C. coli, C. jejuni, indicator commensal E. coli, E. faecalis and E. faecium.
Any E. coli and Salmonella isolate tested in accordance with Table 2 showing resistance to cefotaxime or ceftazidime or meropenem shall be further tested with a second panel of antimicrobial substances in accordance with Table 5.
For the specific monitoring of ESBL-, AmpC- and/or CP-producing E. coli, Member States shall use the methods referred to in point 5.
The antimicrobial susceptibility testing shall be performed by the laboratories referred to in Article 3(2). The testing shall be performed by using the broth micro dilution method according to the reference method ISO 20776-1:2019.
Table 2
Panel of antimicrobial substances to be included in AMR monitoring, EUCAST thresholds for resistance and concentration ranges to be tested in Salmonella spp. and indicator commensal E. coli (First panel)
tentative EUCAST threshold
NA: not available.
Antimicrobial
Class of antimicrobial
Species
Interpretative thresholds of AMR (mg/L)
Range of concentrations (mg/L)(No of wells in brackets)
ECOFF
Clinical breakpoint
Amikacin
Aminoglycoside
Salmonella
> 4
> 16
4-128 (6)
E. coli
> 8
> 16
Ampicillin
Penicillin
Salmonella
> 8
> 8
1-32 (6)
E. coli
> 8
> 8
Azithromycin
Macrolide
Salmonella
NA
NA
2-64 (6)
E. coli
NA
NA
Cefotaxime
Cephalosporin
Salmonella
> 0,5
> 2
0,25-4 (5)
E, coli
> 0,25
> 2
Ceftazidime
Cephalosporin
Salmonella
> 2
> 4
0,25-8 (6)
E, coli
> 0,5
> 4
Chloramphenicol
Phenicol
Salmonella
> 16
> 8
8-64 (4)
E, coli
> 16
> 8
Ciprofloxacin
Fluoroquinolone
Salmonella
> 0,06
> 0,06
0,015-8 (10)
E, coli
> 0,06
> 0,5
Colistin
Polymyxin
Salmonella
NA
> 2
1-16 (5)
E, coli
> 2
> 2
Gentamicin
Aminoglycoside
Salmonella
> 2
> 4
0,5-16 (6)
E, coli
> 2
> 4
Meropenem
Carbapenem
Salmonella
> 0,125
> 8
0,03-16 (10)
E, coli
> 0,125
> 8
Nalidixic acid
Quinolone
Salmonella
> 8
NA
4-64 (5)
E, coli
> 8
NA
Sulfamethoxazole
Folate pathway antagonist
Salmonella
NA
NA
8-512 (7)
E, coli
> 64
NA
Tetracycline
Tetracycline
Salmonella
> 8
NA
2-32 (5)
E, coli
> 8
NA
Tigecycline
Glycylcycline
Salmonella
NA
NA
0,25-8 (6)
E, coli
> 0,5
> 0,5
Trimethoprim
Folate pathway antagonist
Salmonella
> 2
> 4
0,25-16 (7)
E, coli
> 2
> 4
Table 3
Panel of antimicrobial substances to be included in AMR monitoring, EUCAST interpretative thresholds for resistance and concentration ranges to be tested in C. jejuni and C. coli
NA: not available
Antimicrobial
Class of antimicrobial
Species
Interpretative thresholds of AMR (mg/L)
Range of concentrations (mg/L)(No of wells in brackets)
ECOFF
Clinical breakpoint
Chloramphenicol
Phenicol
C. jejuni
> 16
NA
2-64 (6)
C. coli
> 16
NA
Ciprofloxacin
Fluoroquinolone
C. jejuni
> 0,5
> 0,5
0,12-32 (9)
C. coli
> 0,5
> 0,5
Ertapenem
Carbapenem
C. jejuni
NA
NA
0,125-4 (6)
C. coli
NA
NA
Erythromycin
Macrolide
C. jejuni
> 4
> 4
1-512 (10)
C. coli
> 8
> 8
Gentamicin
Aminoglycoside
C. jejuni
> 2
NA
0,25-16 (7)
C. coli
> 2
NA
Tetracycline
Tetracycline
C. jejuni
> 1
> 2
0,5-64 (8)
C. coli
> 2
> 2
Table 4
Panel of antimicrobial substances to be included in AMR monitoring, EUCAST thresholds for resistance and concentration ranges to be tested in E. faecalis and E. faecium
NA: not available
Antimicrobial
Class of antimicrobial
Species
Interpretative thresholds of AMR (mg/L)
Range of concentrations (mg/L)(No of wells in brackets)
ECOFF
Clinical breakpoint
Ampicillin
Penicillin
E. faecalis
> 4
> 8
0,5-64 (8)
E. faecium
> 4
> 8
Chloramphenicol
Phenicol
E. faecalis
> 32
NA
4-128 (6)
E. faecium
> 32
NA
Ciprofloxacin
Fluoroquinolone
E. faecalis
> 4
> 4
0,12-16 (8)
E. faecium
> 4
> 4
Daptomycin
Lipopeptide
E. faecalis
> 4
NA
0,25-32 (8)
E. faecium
> 8
NA
Erythromycin
Macrolide
E. faecalis
> 4
NA
1-128 (8)
E. faecium
> 4
NA
Gentamicin
Aminoglycoside
E. faecalis
> 64
NA
8-1 024 (8)
E. faecium
> 32
NA
Linezolid
Oxazolidinone
E. faecalis
> 4
> 4
0,5-64 (8)
E. faecium
> 4
> 4
Quinupristin/Dalfopristin
Streptogramin
E. faecalis
NA
NA
0,5-64 (8)
E. faecium
NA
> 4
Teicoplanin
Glycopeptide
E. faecalis
> 2
> 2
0,5-64 (8)
E. faecium
> 2
> 2
Tetracycline
Tetracycline
E. faecalis
> 4
NA
1-128 (8)
E. faecium
> 4
NA
Tigecycline
Glycylcycline
E. faecalis
> 0,25
> 0,25
0,03-4 (8)
E. faecium
> 0,25
> 0,25
Vancomycin
Glycopeptide
E. faecalis
> 4
> 4
1-128 (8)
E. faecium
> 4
> 4

---
Source: https://www.legislation.gov.uk/eudn/2020/1729/annex/part/A/division/4/division/4.2 (the official version)
Page: https://openlegislation.uk/eu-decision-2020-1729/annex/part-A/division-4/division-4.2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.